MetaCap

Ligand Pharmaceuticals (LGND) vs Liquidia (LQDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Liquidia (LQDA) has outperformed Ligand Pharmaceuticals (LGND) over the past year, gaining 87.0% versus a gain of 44.0%. Over five years, LQDA leads with a +1224.3% price change compared with +193.2% for LGND. Ligand Pharmaceuticals is the larger company by market cap ($5.74 billion vs $4.90 billion), about 1.2 times the size, while Liquidia is growing revenue faster (+1031.2% vs +60.4%).

On valuation, Liquidia trades at a lower forward P/E (15.1x vs 24.0x for Ligand Pharmaceuticals). Ligand Pharmaceuticals converts more of its revenue into profit, with a net margin of 46.4% versus -43.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LGND+43.98%LQDA+86.98%
+224%+101%-22%
Nov 21, 20251 yearNov 20, 2026
LGND+183.98%LQDA+1177.70%
+2121%+983%-156%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LGND versus LQDA key metrics
MetricLGNDLQDA
Share price$286.85$54.43
Market cap$5.74B$4.90B
1-day change-0.03%-3.88%
YTD return+51.72%+57.81%
1-year return+43.98%+86.98%
5-year return+193.16%+1224.33%
P/E ratio (TTM)115.20—
Forward P/E24.0015.12
EPS (TTM)$2.49$-1.05
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$268.09M$158.32M
Revenue growth (YoY)+60.40%+1031.18%
Net income (latest FY)$124.45M$-68.92M
Operating margin15.29%-32.45%
Net margin46.42%-43.53%
52-week high$326.63$93.61
52-week low$175.89$22.31
Distance from 52-week high-12.18%-41.85%
Analyst consensusstrong_buybuy
Avg. price target upside+25.94%+21.50%
Average volume230.79K3.52M
Shares outstanding20.00M90.11M
Employees47216
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LQDA has outperformed LGND by 43.0 percentage points over the past year.
  • Ligand Pharmaceuticals is more profitable, keeping 46.4 cents of every revenue dollar as net income versus -43.5 cents for Liquidia.
  • Liquidia grew revenue faster in its latest fiscal year (+1031.18% vs +60.40%).

About Ligand Pharmaceuticals

LGND stock →

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees

About Liquidia

LQDA stock →

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees

LGND vs LQDA FAQ

Which is bigger, Ligand Pharmaceuticals or Liquidia?

Ligand Pharmaceuticals (LGND) is larger, with a market capitalization of $5.74B compared with $4.90B for Liquidia (LQDA).

Which stock has performed better over the past year, LGND or LQDA?

LQDA returned +86.98% over the past 12 months, compared with +43.98% for LGND (price return, excluding dividends). Past performance does not predict future results.

Are Ligand Pharmaceuticals and Liquidia in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons